Seikagaku Corp

Chart & Performance

D1W1MN

P/E

19.47

P/S

1.18

EPS

40.05

Div Yield, %

3.59%

Shrs. gr., 5y

-0.68%

Rev. gr., 5y

4.99%

Revenues

36.21b

+8.24%

Net income

2.19b

-2.24%

CFO

513m

-67.41%

Dividend

Mar 28, 20250 JPY/sh

Earnings

Feb 06, 2025

Profile

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.

URL

https://www.seikagaku.co.jp/ja/index.html

IPO date

Mar 23, 2004

Employees

976

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	36,213,000 8.24%	33,456,000 -4.00%	34,851,000 25.99%
Cost of revenue	26,820,000	23,383,000	23,328,000
Unusual Expense (Income)
NOPBT	9,393,000	10,073,000	11,523,000
NOPBT Margin	25.94%	30.11%	33.06%
Operating Taxes	(495,000)	832,000	1,661,000
Tax Rate		8.26%	14.41%
NOPAT	9,888,000	9,241,000	9,862,000
Net income	2,186,000 -2.24%	2,236,000 -40.10%	3,733,000 -12.41%
Dividends	(1,418,000)	(1,560,000)	(1,633,000)
Dividend yield	3.40%	3.47%	3.31%
Proceeds from repurchase of equity		(1,317,000)	73,000
BB yield		2.93%	-0.15%
Debt
Debt current	335,000	337,000	335,000
Long-term debt	157,000	141,000	151,000
Deferred revenue		36,000	36,000
Other long-term liabilities	147,000	109,000	111,000
Net debt	(36,830,000)	(42,658,000)	(45,290,000)
Cash flow
Cash from operating activities	513,000	1,574,000	8,192,000
CAPEX	(4,491,000)	(2,052,000)	(2,050,000)
Cash from investing activities	(7,209,000)	3,365,000	870,000
Cash from financing activities	(1,461,000)	(3,244,000)	(2,151,000)
FCF	3,799,000	5,619,000	11,171,000
Balance
Cash	21,031,000	28,778,000	32,175,000
Long term investments	16,291,000	14,358,000	13,601,000
Excess cash	35,511,350	41,463,200	44,033,450
Stockholders' equity	69,238,000	125,031,000	123,483,000
Invested Capital	37,312,650	26,250,800	22,536,550
ROIC	31.11%	37.88%	42.42%
ROCE	12.54%	14.55%	17.01%
EV
Common stock shares outstanding	54,554	55,239	56,299
Price	765.00 -5.90%	813.00 -7.09%	875.00 -15.38%
Market cap	41,733,810 -7.07%	44,909,307 -8.84%	49,261,625 -15.57%
EV	4,903,810	63,088,307	65,615,625
EBITDA	11,056,000	11,400,000	12,573,000
EV/EBITDA	0.44	5.53	5.22
Interest	4,000	5,000	11,000
Interest/NOPBT	0.04%	0.05%	0.10%